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Abstract
Background: Nitric oxide (NO), produced by endothelial nitric oxide synthase (eNOS), plays a key role in the
regulation of vascular tone. Endothelium-derived NO exerts vasoprotective effects by suppressing platelet
aggregation, leukocyte adhesion and smooth muscle cell proliferation. The E298D polymorphic variant of eNOS has
been associated with myocardial infarction (MI), but data relating to this variant are divergent in Greece.
Accordingly, we examined a possible association between the E298D polymorphism of the eNOS gene and MI in a
subgroup of the Greek population.
Methods: The study population consisted of 204 patients with a history of MI and 218 control subjects. All
subjects were of Greek origin and were selected from the general population of the greater Athens area.
Genotyping was performed with melting curve analysis (Lightcycler system) of polymerase chain reaction amplified
products using hybridization probes.
Results: According to the univariate findings, the risk for MI in E298D TT was 2.06 (95%CI: 1.06-4.00, p = 0.032)
versus GG+GT and 2.34 (95%CI: 1.17-4.68, p = 0.016) versus GG. The risk for the T allele was estimated at 1.42 (95%
CI, 1.06-1.89, p = 0.022) as compared to G allele. Regarding the additive model, one allele increase was associated
with 43% higher risk of MI (OR = 1.43, 95%CI: 1.07-1.93, p = 0.018) as compared to the baseline category of
homozygous GG. The positive association of TT versus GG+GT with MI risk remained even after adjusting for the
main study covariates. Moreover, strong evidence was found for an increased risk for MI among carriers of the TT
genotype who were smokers, hypertensive and had a family history of CAD.
Conclusions: This study indicates that E298D polymorphism of the eNOS gene seems to be associated with MI
occurrence in the Greek population. It is possible that TT genotype is closely linked to the etiology of MI even after
adjusting for known MI risk factors.
Background
Nitric oxide (NO), the endothelium-derived relaxing fac-
tor, is synthesized from L-arginine by at least three iso-
forms of the Nitric Oxide Synthase (NOS) (inducible
NOS, iNOS or NOS2, constitutive neuronal NOS,
nNOS or NOS1 and constitutive endothelial NOS,
eNOS or NOS3). Nitric oxide, produced by eNOS, dif-
fuses from the endothelium to vascular smooth muscle
cells, where it increases the concentration of cyclic
guanosine monophosphate (cGMP) by stimulating solu-
ble guanylate cyclase, leading to vascular relaxation [1].
Endothelium-derived NO plays a key role in the regu-
lation of vascular tone and displays vasoprotective
effects by scavenging superoxide radicals [2] and sup-
pressing platelet aggregation [3], leukocyte adhesion [4]
and smooth muscle cell proliferation [5]. These actions
suggest that endothelial NO may have an important
atheroprotective role. Thus, an alteration in the activity
of the vascular NO system could contribute to the
pathogenesis of atherosclerosis and thrombosis.
The gene encoding eNOS is located on chromosome
7q35-36 and contains 26 exons that span 21 kb [6]. The
common polymorphism G
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any medium, provided the original work is properly cited.gene results in the substitution of glutamic acid (E) at
codon 298 by aspartic acid (D) (E298D). This is the only
known polymorphism changing the eNOS protein
sequence, leading to speculation that genetic variation at
this site may alter e-NOS activity or regulation and pos-
sibly leads to endothelial dysfunction and to pathogen-
esis of several cardiovascular diseases [7].
The 298D variant has been associated with myocardial
infarction (MI) in Japanese [8,9], English [10], German
[11] and American [12] populations, whereas other stu-
dies do not support these findings in Koreans [13,14]
and in Caucasians, i.e. Austrian [15] French-Nothern
Irish [16] and Dutch [17] populations. In Greece studies
of the E298D polymorphism had controversial results
[18-20]. Accordingly, it was the aim of the present study
to investigate in a subgroup of the Greek population
whether the E298D gene variation was related to the
risk of myocardial infarction in the total population and
among subjects who were at lower or higher risk of this
disease.
Methods
Study population
A total of 422 subjects of Greek origin were prospec-
tively enrolled in the study. Among them, 204 patients,
diagnosed with an Acute Myocardial Infarction (AMI)
or Non ST Segment Elevation Myocardial Infarction
(NSTEMI) were compared to 218 control subjects.
The 204 patients with MI admitted to the 1st Depart-
ment of Cardiology, Onassis Cardiac Surgery Center
Athens, Greece from October 2007 to April 2008. Diag-
nosis of AMI and NSTEMI was made by chest symp-
toms, electrocardiographic changes and serum
creatinine kinase-MB isoenzyme (CK-MB) elevations
according to guidelines [21].
The control group consisted of 218 volunteers who
were selected from the general population of the greater
Athens area. Controls were not eligible to participate if
they had a history of MI or angina, clinical evidence of
coronary artery disease (CAD), stroke, or any athero-
sclerotic disease in the past, based on a detailed medical
history and a physical examination followed by a normal
electrocardiogram.
All subjects provided written informed consent and
the study was approved by the hospital ethics commit-
tee. Subjects were evaluated with a detailed question-
naire that provided information on coronary risk factors,
namely smoking, family history of CAD, hypertension,
diabetes mellitus and hypercholesterolemia. Patients
who used to smoke more than eight cigarettes per day
for more than one year were considered to be smokers
(current or ex-smokers). Body mass index (BMI) was
calculated in all participants.
MI patients and controls were matched by gender and
age ± five years. Controlling for basic socio-demographic
characteristics in the statistical analysis, minimized
further the consequences of potential confounding by
those variables.
Coronary risk factors
Hypertension was defined by a history of several blood
pressure measurements with elevation of either systolic
(> 140 mmHg) or diastolic (> 90 mmHg) blood pres-
sure. Diabetes mellitus was defined by elevated blood
glucose levels after fasting: (> 126 mg/dL) or 2 h after
75 g of oral glucose loading (> 200 mg/dL), or by anti-
diabetic drug. Hypercholesterolemia was defined by ele-
vated total serum cholesterol levels (> 200 mg/dL).
DNA extraction and genotyping
Genomic DNA was extracted from peripheral blood leu-
kocytes using standard methods (Micromix 660 DNA
extraction kit, Talent, Italy). Purified DNA (concentration
of 60 μg/ml) was stored at -20°C. The E298D polymorph-
ism was determined by Real-Time Polymerase Chain
Reaction analysis using the LightCycler 480 Instrument
(Roche Diagnostics, Mannheim, Germany). The pub-
lished probes [22] were found to fail to detect homozy-
gous TT samples. Thus, novel oligonucleotide primers
a n dp r o b e sw e r ed e s i g n e da n dv a l i d a t e db yT I B -
MOLBIOL, Berlin, Germany. The kit contains control
DNA (human eNOS 298D mutant [mt], wild type [wt],
heterozygous [hetero], 10
5 target equivalents per reac-
tion). PCR primers 5’-AAggCAggAgACAgTggATggA
and 5’-TgCTCCAggggCACCTCAAg and the probes
CCAgATgATCCCCTAgAACTC–FL (T allele specific
base underlined) and 640-CCTTCTgCCCCCCgAgC
TggTCC–PH contained in the LightMix kit eNOS (TIB
MOLBIOL, Berlin, Germany) were used in combination
with the LightCycler 480 Genotyping Master and 96 well
plates (Roche Diagnostics, Mannheim, Germany), follow-
ing the instructions of the manufacturer. The tests were
run with 5 μl( 0 . 3μg) sample DNA in a final volume of
20 μl; control DNA (human eNOS 298D [mt], [wt], [het-
ero]) was diluted 1:4. Each PCR run contained a negative
(no template) control. To confirm reproducibility, muta-
tion analysis of 9 random samples (3 wt/wt, 3 wt/mt and
3 mt/mt) was performed 10 times each.
The probes are designed to match with the T allele,
thus reporting a lower melting temperature (Tm) for
the wild type G allele. Distinction of wild type, mutant
and heterozygous genotype can be easily accomplished
by their respective melting temperatures.
After 10 min denaturation at 95°C the amplification
w a sp e r f o r m e dr u n n i n g4 5c y c l e s5sa t9 5 ° C ,1 0sa t
60°C and 15 s at 72°C, following the instructions of the
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denaturalization at 95°C for 30 s, renaturation at 40°C
for 1 min and then slowly raised to 80°C to allow moni-
toring of the decline of fluorescence generated by melt-
ing of the hybrids, as a function of temperature. Melting
curves were automatically converted to fluorescence
peaks with the LightCycler 480 Instrument analysis soft-
ware, allowing the distinction of genotypes. The group-
ing software uses a curve shape-matching algorithm to
identify wild type from mutant samples and cut-offs are
based on variability from the wild type curve. The
results were confirmed for homozygous mutant, homo-
zygous wild type and heterozygous samples in all
repeated measurements.
Statistical analysis
Body mass index (BMI) was regarded as continuous
variable, while age, gender, kind of genotype, and pre-
sence of all coronary risk factors (smoking, family his-
tory of CAD, hypertension,d i a b e t e sm e l l i t u sa n d
hypercholesterolemia) were considered nominal vari-
ables. Initially, t test for continuous data and c
2 for cate-
gorical data were used to assess the differences in socio-
demographic and medical history factors between cases
and controls. Genotype frequencies of E298D poly-
morphism were compared in the two groups of partici-
pants with Fisher’s exact test. To study the univariate
association of MI with the eNOS genotype we modeled
the data through logistic regression analysis (crude odds
ratios); the relevant p-values derived from Wald test for
dominant and recessive models and Armitage test for
trend for additive model. Subsequently, a multivariate
analysis was performed to estimate the risk of MI for
TT versus GT+GG after adjustment for a series of pos-
sible risk factors and confounders (adjusted odds ratios).
Results were accepted as statistically significant when
two-tailed p-values were less than 0.05. The SAS statisti-
cal package (Version 9.1, SAS Institute Inc, Cary, NC)
was used in all analyses whereas power calculation was
performed on QUANTO.
Results
Univariate analyses
Setting minor allele frequency (MAF) at 0.3, expected
odds ratio from 1.5 to 2.5 (univariate odds ratio for the
relationship between TT/GG+GT and the risk for MI),
alpha 0.05 and power 80%, on QUANTO, mode of
inheritance seems to result in an odds ratio of at least 2.3.
Table 1 shows the distribution of 204 cases with MI
and 218 controls by socio-demographic and clinical
characteristics. Regarding age and gender, no significant
differences were identified between cases and controls
(p = 0.580 and p = 0.658 respectively). The mean BMI
was significantly higher in cases as compared to controls
(p = 0.028). The prevalence of atherogenic risk factors
such as smoking, family history of CAD, hypertension,
diabetes mellitus and hypercholesterolemia was signifi-
cantly higher in the patient group.
Table 2 presents the distribution of genotypes GG, GT
and TT in the two groups of participants. The frequen-
cies of the eNOS GG genotype were 40.7% and 49.5%,
of heterozygous GT 46.1% and 43.6% and of homozy-
gous TT 13.2% and 6.9% among cases and controls
respectively. This difference was statistically significant
(p = 0.046). Concerning the allele frequencies of the
Table 1 Demographic and clinical characteristics of
myocardial infarction (MI) among patients and controls
Variables MI Patients
(n = 204)
Controls
(n = 218)
P-value
†
Age (years) 0.580
< 60 104 (51.0) 117 (53.7)
60+ 100 (49.0) 101 (46.3)
Gender 0.658
Male 178 (87.2) 187 (85.8)
Female 26 (12.8) 31 (14.2)
BMI (kg/m
2) 26.88 ± 3.47 26.19 ± 2.92 0.028
Smoking < 0.0001
No 37 (18.1) 99 (45.4)
Yes 167 (81.9) 119 (54.6)
Family history of CAD < 0.0001
No 119 (58.3) 195 (89.5)
Yes 85 (41.7) 23 (10.5)
Hypertension < 0.0001
No 59 (28.9) 167 (76.6)
Yes 145 (71.1) 51 (23.4)
Diabetes mellitus < 0.0001
No 131 (64.2) 208 (95.4)
Yes 73 (35.8) 10 (4.6)
Hypercholesterolemia < 0.0001
No 28 (13.7) 198 (90.8)
Yes 176 (86.3) 20 (9.2)
Data are presented as mean ± SD or N (%).
†P-values derived from t-test for continuous variables; chi-square test was
used for categorical variables.
Table 2 Genotype frequencies of E298D polymorphism in
MI patients and controls
eNOS E298D
Polymorphism
MI Patients
N (%)
Controls
N (%)
P-value
†
eNOS 0.046
GG 83 (40.7) 108 (49.5)
GT 94 (46.1) 95 (43.6)
TT 27 (13.2) 15 (6.9)
allele 0.019
G 260 (63.7) 311 (71.3)
T 148 (36.3) 125 (28.7)
†P-values derived from genotypic and allelic Fisher’s exact tests.
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calculated at 36.3% and 28.7% respectively (p = 0.019).
In the univariate analyses of the data (Table 3), TT
homozygous, compared with the group of homozygous
and heterozygous individuals GG+GT (recessive model),
were at higher risk for MI (OR = 2.06, 95%CI = 1.06-
4.00, p = 0.032). Even if TT homozygous were com-
pared with E298 homozygous GG alone, they were still
more likely to develop MI (OR = 2.34, 95%CI: 1.17-4.68,
p = 0.016). We found no statistical significant evidence
for a protective effect against the risk for MI among
homozygous GG as compared to heterozygous GT (p =
0.220), whereas when comparing them to GT+TT
(dominant model) the result was not significant (p =
0.068). According to the additive model, one allele
increase was associated with 43% higher risk of MI (OR
= 1.43, 95%CI: 1.07-1.93, p = 0.018) as compared to the
baseline category of homozygous GG.
Multivariate analyses
Based on the univariate findings suggesting an increased
risk for TT homozygous and the idea that the recessive
model of inheritance seems to be more appropriate than
dominant or additive for the needs of such a research
[23], we further performed multivariate analyses in
order to examine the relation of MI with a series of
available parameters. Due to the presence of mutual
confounding, correlation or interaction, it was not possi-
ble to examine all the study covariates simultaneously.
Several alternative statistical models are performed and
presented in Table 4. In all these models, homozygous
TT as compared to GT+GG were found to be at statisti-
cally significant higher risk for developing MI with the
estimated odds ratios ranging from 2.04 to 2.89. Gender
does not seem to be associated with the risk for MI,
whereas the effect of age is unclear. There was some
evidence that increasing BMI increases the risk for MI,
but the results were at the borderline of statistical
Table 3 Logistic regression-derived, crude odds ratios
(ORs) and 95% confidence intervals (CIs) for the risk of
myocardial infarction (MI) in carries of the 298D allele
among the study participants
eNOS E298D Crude analysis
ORs 95% CI P-value
Recessive model
TT vs GG+GT 2.06 1.06-4.00 0.032*
Dominant model
GG vs GT+TT 0.70 0.48-1.03 0.068*
Additive model
T allele vs GG 1.43 1.07-1.93 0.018**
Other models
TT vs GG 2.34 1.17-4.68 0.016*
TT vs GT 1.82 0.91-3.64 0.090*
T allele vs G allele 1.42 1.06-1.89 0.022*
GG vs GT 0.78 0.52-1.16 0.220*
*P-values derived from Wald test.
** P-value derived from Armitage test for trend.
Table 4 Logistic regression-derived odds ratios (ORs) and 95% confidence intervals (95% CIs) for the risk of
myocardial infarction (MI) by eNOS E298D, controlling for demographic and medical history variables among the 422
study participants
Variable Category or increment ORs
1 (95% CIs) ORs
2 (95% CIs) ORs
3 (95% CIs) ORs
4 (95% CIs) ORs
5 (95% CIs)
p-value p-value p-value p-value p-value
eNOS E298D TT vs. GT+GG 2.06 (1.06-4.00) 2.04 (1.05-3.96) 2.41 (1.18-4.92) 2.57 (1.18-5.60) 2.89 (1.11-7.51)
0.032 0.036 0.016 0.018 0.029
Age 60+ vs. < 60 years 1.11 (0.75-1.65) 1.76 (1.13-2.75) 2.24 (1.38-3.64) 1.00 (0.54-1.80)
0.602 0.013 0.001 0.969
Gender female vs. male 0.86 (0.48-1.53) 1.26 (0.67-2.37) 1.19 (0.62-2.30) 1.37 (0.66-2.87)
0.606 0.470 0.608 0.401
BMI 2 kg/m
2 more 1.14 (1.00-1.30) 1.13 (0.98-1.30) 1.12 (0.97-1.30)
0.057 0.096 0.132
Smoking yes vs. no 4.93 (2.98-8.15) 5.53 (3.21-9.54) 6.83 (3.64-12.84)
< 0.0001 < 0.0001 < 0.0001
Family history of CAD yes vs. no 6.97 (3.98-12.21) 6.91 (3.69-12.94)
< 0.0001 < 0.0001
Hypertension yes vs. no 11.91 (6.70-21.17)
< 0.0001
1 = Model 1: Unadjusted odds ratio for eNOS E298D.
2 = Model 2: Odds ratio for mutually adjusted eNOS E298D, age and gender.
3 = Model 3: Odds ratio for mutually adjusted eNOS E298D, age, gender, BMI and smoking.
4 = Model 4: Odds ratio for mutually adjusted eNOS E298D, age, gender, BMI, smoking and family history of CAD.
5 = Model 5: Odds ratio for mutually adjusted eNOS E298D, age, gender, BMI, smoking, family history of CAD and hypertension.
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tically significant, positive association of MI with smok-
ing, family history of CAD and hypertension. The small
cell frequencies of diabetes mellitus and hypercholester-
olemia did not allow us to include these two variables in
the multivariate analyses.
Discussion
We performed a case-control study of the common
E298D polymorphism of the eNOS gene. Similarly to
recent studies [8-11,13,17-20], we found a significant
association between homozygous carriers of the T allele
and the occurrence of MI in the Greek population. The
risk of developing MI was found to be about two-fold
higher for 298D (homozygous carriers of the T allele) as
compared with individuals carrying the wild type E298
allele, either heterozygous (GT) or homozygous (GG)
(p = 0.032). Lack of an increased risk of MI in the
eNOS GT heterozygous suggests that the risk of MI
posed by the eNOS T allele is not dominantly expressed
a n dt h a tt h ei n c r e a s e dr i s ki sc o n f i n e dt oe N O ST T
homozygous. This finding confirms previous presump-
tions of a recessive gene effect. Patients who are homo-
zygous for the E298D polymorphism are genetically
predisposed to MI (Table 3). The results of the present
study are in accordance with the findings of a recent
meta-analysis of the Glu298Asp polymorphism, includ-
ing 14 studies with 6036 IHD cases and 6106 controls.
According to this meta-analysis, the summary OR under
a fixed-effect model showed that individuals homozy-
gous for the Asp298 allele were 1.31 times more likely
to develop ischemic heart disease (95% CI, 1.13 to 1.51;
p = 0.0003) whereas the dominant model showed a
non-significant association between carriers of ≥1
Asp298 allele and the risk of ischemic heart disease
(OR, 1.06; 95% CI, 0.97 to 1.15; p=0.21) [23].
MI is a multifactorial disease. Further genetic and
environmental risk factors, such as age, gender, BMI,
smoking habits and family history as well as accompany-
ing disorders like high blood pressure and hypercholes-
terolemia contribute significantly to the susceptibility of
MI.
The homozygous T allele carriers, as suggested by the
univariate analysis of the present study, have an
increased risk to develop MI. We performed a multivari-
ate analysis to examine the additive influence of age,
gender, BMI, smoking habits and family history to the
TT genotype. The increased risk of the TT gene
remains even if we add the variables smoking, hyperten-
sion and family history. BMI seems to tentatively elevate
MI risk, while gender seems to be unrelated to MI. Data
from a recent study confirmed that predominantly
younger T allele carriers of the eNOS E298D gene poly-
morphism with various coronary high-risk profiles have
an increased risk to suffer MI [11]. Taking into account
that the cardiovascular disease is a multicausal process
and since other than genetic risk factors develop in the
course of life, genetic factors are more likely to affect
young rather than old people and may contribute to
many different mechanisms leading to atherosclerotic
lesions [24,25]. Nevertheless, our study does not confirm
those findings since the role of age remained unclear.
The association between eNOS E298D polymorphism
and MI is strongly affected by cigarette smoking. In a
previous study it was demonstrated that the variant 298D
allele is particularly associated with significantly lower
endothelial-dependent vasodilation in smokers, with no
significant effect in non-smokers [26]. We observed that
the combination of smoking and 298D allele further
increased OR for MI, suggesting that there is a gene-
environment interaction. Smokers, eNOS TT homozy-
gous have greater risk of MI than eNOS GT heterozy-
gous and GG homozygous smokers. These data, possibly
suggest, that presence of established underlying endothe-
lial dysfunction, as observed among cigarette smokers,
may be necessary for this polymorphism to attenuate
endothelial function and predispose patients to increased
cardiovascular risk. The impact of smoking, however, in
females could not be demonstrated. It has been reported
that the development of endothelial dysfunction and
atherosclerosis in premenopausal females may follow a
different pattern than in men, probably due to estrogen-
mediated protection of the endothelium [26].
The results of the present study strongly suggest that
eNOS gene may be a risk factor for MI. Although the
mechanism by which E298D polymorphism confers sus-
ceptibility to MI is not clear, several studies have
described a possible role of NO in the pathogenesis of
MI and suggest that endothelial NO may have an impor-
tant atheroprotective role beyond its effect on vessel tone
and blood pressure [27,28]. This study suggests that an
alteration in the activity of the vascular NO system and
the decreased amount of endothelial NO, due to the
E298D mutation, may promote atherosclerosis and
thrombosis that lead to MI. However, the relation of the
E298D mutation to the severity of coronary atherosclero-
sis has not been proven yet [8]. Impaired effects of NO
on the cardiovascular system lead to dysregulation of vas-
cular tone, platelet aggregation and leukocyte adhesion
and smooth muscle cell proliferation, all of which pro-
mote coronary atherosclerosis and thrombosis [9].
Two previous studies showed a significant association
between the 298D allele and the risk of MI in the Greek
population [18,19]. A third study by Andrikopoulos et al
[20] failed to demonstrate such an association.
This study adds to the gradually developing consensus
that E298D polymorphism of the eNOS gene seems to
be associated with MI occurrence. It is possible that TT
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ing for known MI risk factors. The underlying mechan-
isms are still speculative but it appears that further
studies are needed to explore whether E298D poly-
morphism is an independent risk factor or an indirect
marker of different genetic and environmental factors.
Study Limitations
No case control study is immune to criticism concern-
ing case and control selection and the present one is no
exception. However, the identification in the present
study of most established risk factors for MI indicates
that possible selection and information biases were not
important enough to challenge the validity of the results.
We have no reason to believe that cases were not repre-
s e n t a t i v eo fp e o p l es u f f e r i n gM Ii nt h ec o u n t r y .H o w -
ever, because of the overall low frequency of TT (15
subjects with TT genotype in the control group and 27
in the case group), the results should be viewed with
caution. Notably, given the expected low frequency of
TT in the general population, this type of studies face
practical difficulties in achieving high number of partici-
pants. Further studies could provide an insight into the
role of E298D polymorphism of the eNOS gene in the
MI occurrence.
Conclusions
This study indicates that E298D polymorphism of the
eNOS gene seems to be associated with MI occurrence
in the Greek population. We found evidence that homo-
zygous TT is positively related to the risk of MI and
this association is independent of possible effects of
other known MI risk factors. Smokers, hypertensive and
those with a family history of CAD are more likely to
develop MI.
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